Pencil Banner October 16 2023

Elevar Therapeutics and Jiangsu Hengrui Pharma announce global commercialization licensing agreement for camrelizumab in combination with rivoceranib for hepatocellular carcinoma LEARN MORE HERE

ASCO 2020

ASCO Annual Meeting 2020 Poster Report of Rivoceranib in Recurrent or Metastatic Adenoid Cystic Carcinoma

This poster was presented at the 2020 ASCO Annual Meeting. It presents a Phase II study evaluating safety and efficacy of rivoceranib in patents with recurrent or metastatic adenoid cystic carcinoma. This phase 2 multi-center aims to evaluate efficacy measured by ORR in ACC patients in the US and South Korea. To read the full study report download the poster.